The correlation between chronic conditions and the benefits of patient self-administration continues to influence therapeutic product decisions, managed care initiatives and regulatory actions. The administration of injectables is moving increasingly from practitioner offices and healthcare facilities to patient homes. Decisions regarding as-supplied packaging that were once considered boilerplate have moved to the early stages of the development process. Responding to these market forces, drug developers and their device partners are increasing their emphasis on device features and functionality, attempting to create injectable products that are more user-friendly while promoting patient adherence and safety. These features address a wide spectrum of device attributes, including form factor, device-patient interaction, security and safety, dosing, activation, off-device communication, and drug formulation factors.